Technology
Health
Pharmaceutical

SCYNEXIS

$1.48
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
-$0.09 (-5.73%) After Hours

Why Robinhood?

You can buy or sell SCYNEXIS and other stocks, options, ETFs, and crypto commission-free!

About

SCYNEXIS, Inc. Common Stock, also called SCYNEXIS, is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. Read More The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Employees
24
Headquarters
Jersey City, New Jersey
Founded
1999
Market Cap
75.32M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
665.59K
High Today
$1.60
Low Today
$1.51
Open Price
$1.56
Volume
192.89K
52 Week High
$2.15
52 Week Low
$0.35

Collections

Technology
Health
Pharmaceutical
2014 IPO
US
North America

News

Markets InsiderMar 14

SCYNEXIS Reports Full Year 2018 Financial Results and Provides Company Update

JERSEY CITY, N.J., March 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today reported financial results for the year ended December 31, 2018, and provided an update on recent operational and clinical developments. "We ended 2018 having accomplished meaningful progress across our ibrexafungerp clinical development programs, including positive results from our Phase 2b DOVE study ev...

2,490
PR NewswireMar 7

SCYNEXIS is Retiring Existing Term Loan Through a Lower-Interest and Longer-Term Convertible Note

JERSEY CITY, N.J., March 7, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the sale of a $16.0 million aggregate principal amount of 6.0% convertible senior note due 2025 (the "note"). The note was sold in a private offering to Puissance Capital Management pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The sale of the note i...

1,667
PR NewswireFeb 28

SCYNEXIS to Present Pre-clinical Data Supporting Prophylactic Use of Ibrexafungerp at Superbugs and Superdrugs 2019

JERSEY CITY, N.J., Feb. 28, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present new in vivo data supporting the potential use of oral ibrexafungerp (formerly SCY-078) for the prevention and treatment of Pneumocystis pneumonia (PCP), a significant risk for immunocompromised patients. The presentation will take place on March 18th at 4PM GMT at Sup...

2,580

Earnings

-$0.34
-$0.22
-$0.11
$0.01
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.14 per share
Actual
-$0.10 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.